文献速递系统性红斑狼疮

BEL-Spain注册研究:贝利尤单抗联合免疫抑制剂是否在SLE中带来额外获益?

Does adding concomitant immunosuppressive therapy to belimumab provide additional benefits in SLE? Results from the BEL-Spain Registry.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该回顾性研究基于BEL-Spain注册数据,纳入258例接受贝利尤单抗治疗且随访至少12个月的SLE患者,其中177例(68.6%)联用免疫抑制剂,81例(31.4%)单药治疗。12个月时两组DORIS缓解率分别为48.1%和51.4%(P=NS),倾向评分加权后缓解率无显著差异(OR 0.89,95%CI 0.37-2.14),LLDAS和复发率亦相当。结论提示在部分SLE患者中,贝利尤单抗单药治疗可实现与联合免疫抑制剂相似的结局。

要点

  • 贝利尤单抗单药与联合免疫抑制剂在12个月DORIS缓解率上无显著差异。
  • 倾向评分加权后缓解率OR为0.89(95%CI 0.37-2.14),证实无显著差异。
  • 两组LLDAS和复发率相当,且均观察到糖皮质激素逐步减量。

核心结论

  • 在真实世界队列中,贝利尤单抗单药治疗在部分SLE患者中与联合免疫抑制剂取得相似的临床结局。

研究设计与样本

  • 回顾性分析BEL-Spain注册中接受贝利尤单抗治疗且随访至少12个月的SLE患者,比较单药与联合免疫抑制剂两组,并采用重叠倾向评分加权调整适应证混杂。

主要发现

  • 258例患者中177例(68.6%)接受贝利尤单抗联合免疫抑制剂,81例(31.4%)接受单药治疗。
  • 12个月时DORIS缓解率联合组为48.1%,单药组为51.4%(P=NS),LLDAS和复发率两组相当。
  • 倾向评分加权分析显示缓解率无显著差异(OR 0.89,95%CI 0.37-2.14)。
  • 两组总体治疗轨迹稳定,均观察到糖皮质激素逐步减量。

关键数值与推荐

  • 主要结局为2021年DORIS定义缓解,次要结局包括LLDAS、复发率和糖皮质激素使用。
  • 12个月DORIS缓解率:联合免疫抑制剂组48.1%,单药组51.4%(P=NS)。
  • 倾向评分加权后缓解率OR 0.89(95%CI 0.37-2.14)。

临床怎么用

  • 对于已实现疾病控制的特定SLE患者,可考虑贝利尤单抗单药治疗以减少免疫抑制剂暴露。
  • 贝利尤单抗治疗中应持续监测疾病活动度,并根据情况逐步减少糖皮质激素用量。

局限性

  • 本研究为回顾性观察性分析,存在适应证混杂可能,即使采用倾向评分加权仍不能完全排除。
  • 样本量有限(258例),单药组仅81例,可能影响统计效能。
  • 随访时间至少12个月,长期结局未报告。
  • 结论需前瞻性研究进一步确认并明确最佳治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Belimumab (BEL) is an approved biologic therapy for systemic lupus erythematosus (SLE) that, when added to standard care, reduces disease activity, flare rates and glucocorticoid exposure. In clinical practice, BEL is frequently combined with conventional immunosuppressants (IS), but the added benefit of concomitant IS once disease control is achieved remains uncertain. Observational data suggest that BEL monotherapy may be effective in selected patients, but comparative real-world evidence is limited. Objectives were to evaluate the clinical effectiveness of BEL as monotherapy vs in combination with IS in patients with SLE included in the BEL-Spain Registry. METHODS: We performed a retrospective analysis of SLE patients treated with BEL with or without IS, with at least 12 months of follow-up. The primary outcome was remission according to the 2021 DORIS definition. Secondary outcomes included Lupus Low Disease Activity State (LLDAS), flare rates and glucocorticoid use. Overlap propensity score weighting was applied to adjust for confounding by indication. RESULTS: Among 258 patients, 177 (68.6%) received BEL with IS and 81 (31.4%) BEL monotherapy. At 12 months, DORIS remission rates were 48.1% in the IS group and 51.4% in the monotherapy group (P=NS), with comparable LLDAS and flare rates. Propensity score-adjusted analyses confirmed no significant differences in remission rates (OR 0.89, 95% CI 0.37-2.14). Global treatment trajectories were stable, other than progressive glucocorticoid reduction in both groups. CONCLUSION: In this real-world cohort, BEL monotherapy achieved similar outcomes to combination therapy with IS in selected SLE patients. Prospective studies are needed to confirm these findings and define optimal treatment strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Frade-Sosa B, Gómez-Puerta JA, Altabás-González I, et al. Does adding concomitant immunosuppressive therapy to belimumab provide additional benefits in SLE? Results from the BEL-Spain Registry. Rheumatology (Oxford). 2026. PMID: 41649458. doi:10.1093/rheumatology/keag076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。